China Pharma Eyes Brighter SE Asia Markets Amid US Entry Shadows
Executive Summary
Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.
You may also be interested in...
Aurobindo Reverses Roles With Pfizer As It Drops Pin On Indonesia: What’s The Draw?
Aurobindo’s acquisition of 15 brands from Pfizer and Viatris to gain entry to Indonesia marks a role reversal of sorts as Pfizer has been licensing generics from Aurobindo. Scrip takes a look at some of the opportunities and challenges in this growing Southeast Asian market.
'Still Bad Out There' - Drug Makers In APAC Prepare For Worst Before It Gets Better
Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.
Chinese Language Podcast: 出海新动向，数据出境，药监新政和后疫情的疫苗
The latest China biopharma trends, including Chinese biotech firms going overseas, post-COVID vaccine developments, new overseas data transfer standard contracts and developments at the Center for Drug Evaluation, are discussed in this Chinese-language podcast with Brian Yang in Beijing and Dexter Yan in Shanghai.